UNI-MB - logo
UMNIK - logo
 

Rezultati iskanja

Osnovno iskanje    Izbirno iskanje   
Iskalna
zahteva
Knjižnica

Trenutno NISTE avtorizirani za dostop do e-virov UM. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 551.072
1.
  • CD19/CD22 Dual‐Targeted CAR... CD19/CD22 Dual‐Targeted CAR‐T Therapy Active in Relapsed/Refractory DLBCL
    The oncologist (Dayton, Ohio), July 2020, Letnik: 25, Številka: S1
    Journal Article
    Recenzirano
    Odprti dostop

    AUTO3, the first chimeric antigen receptor (CAR) T‐cell therapy targeting both CD19 and CD22, shows promise in combination with pembrolizumab in patients with relapsed/refractory diffuse large B‐cell ...
Celotno besedilo

PDF
2.
  • Pembrolizumab Improves Prog... Pembrolizumab Improves Progression‐Free Survival in Relapsed/Refractory Hodgkin Lymphoma
    The oncologist (Dayton, Ohio), July 2020, Letnik: 25, Številka: S1
    Journal Article
    Recenzirano
    Odprti dostop

    In the phase III KEYNOTE‐204 trial, pembrolizumab significantly improved progression‐free survival compared with brentuximab vedotin in patients with relapsed or refractory classic Hodgkin lymphoma ...
Celotno besedilo

PDF
3.
Celotno besedilo

PDF
4.
  • CIBMTR Analysis Confirms On... CIBMTR Analysis Confirms Ongoing Role for Autologous Transplant in Chemosensitive Relapsed DLBCL
    The oncologist (Dayton, Ohio), July 2020, Letnik: 25, Številka: S1
    Journal Article
    Recenzirano
    Odprti dostop

    In the era of chimeric antigen receptor (CAR) T‐cell therapy for relapsed/refractory diffuse large B‐cell lymphoma (DLBCL), a new analysis from the Center for International Blood & Marrow Transplant ...
Celotno besedilo

PDF
5.
  • Venetoclax Boosts Benefits ... Venetoclax Boosts Benefits of R‐EPOCH in Aggressive B‐Cell Lymphomas
    The oncologist (Dayton, Ohio), July 2020, Letnik: 25, Številka: S1
    Journal Article
    Recenzirano
    Odprti dostop

    Adding venetoclax to standard chemoimmunotherapy with R‐EPOCH showed promising antitumor activity in two lymphoma trials: a phase II trial of patients with previously untreated or relapsed/refractory ...
Celotno besedilo

PDF
6.
  • Time‐Limited Triplet Therap... Time‐Limited Triplet Therapy Induces Rapid Undetectable MRD Responses in CLL
    The oncologist (Dayton, Ohio), July 2020, Letnik: 25, Številka: S1
    Journal Article
    Recenzirano
    Odprti dostop

    Zanubrutinib, obinutuzumab, and venetoclax (BOVen), given on a treatment schedule driven by minimal residual disease milestones, is a promising approach to previously untreated chronic lymphocytic ...
Celotno besedilo

PDF
7.
Celotno besedilo

PDF
8.
Celotno besedilo

PDF
9.
  • Generalized Sarymsakov Matr... Generalized Sarymsakov Matrices
    Xia, Weiguo; Liu, Ji; Cao, Ming ... IEEE transactions on automatic control, 08/2019, Letnik: 64, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    Within the set of stochastic, indecomposable, aperiodic (SIA) matrices, the class of Sarymsakov matrices is the largest known subset that is closed under matrix multiplication, and more critically ...
Celotno besedilo

PDF
10.
  • VIII ALL-RUSSIAN CONFERENCE... VIII ALL-RUSSIAN CONFERENCE ON ATMOSPHERIC ELECTRICITY
    P.P. Firstov; V. I Kozlov; E. I. Malkin Vestnik KRAUNT͡S︡: fiziko-matematicheskie nauki, 11/2019, Letnik: 29, Številka: 4
    Journal Article
    Recenzirano
    Odprti dostop

    From September 23 to September 27, 2019, the VIII All-Russian Conference on Atmospheric Electricity was held in Nalchik. The conference was organized by the Russian Academy of Sciences, the A.F. ...
Celotno besedilo

PDF
1 2 3 4 5
zadetkov: 551.072

Nalaganje filtrov